Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Cerilliant
Moodys
Daiichi Sankyo
US Army
Novartis
Cantor Fitzgerald
Federal Trade Commission
AstraZeneca
Merck

Generated: January 17, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020397

« Back to Dashboard

NDA 020397 describes ZANAFLEX, which is a drug marketed by Acorda and is included in two NDAs. It is available from eight suppliers. Additional details are available on the ZANAFLEX profile page.

The generic ingredient in ZANAFLEX is tizanidine hydrochloride. There are eleven drug master file entries for this compound. Fifty-one suppliers are listed for this compound. Additional details are available on the tizanidine hydrochloride profile page.
Summary for 020397
Tradename:ZANAFLEX
Applicant:Acorda
Ingredient:tizanidine hydrochloride
Patents:0
Therapeutic Class:Antispasticity Agents
Formulation / Manufacturing:see details
Pharmacology for NDA: 020397
Mechanism of ActionAdrenergic alpha2-Agonists
Suppliers and Packaging for NDA: 020397
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ZANAFLEX tizanidine hydrochloride TABLET;ORAL 020397 NDA Acorda Therapeutics, Inc. 10144-594 10144-594-15 150 TABLET in 1 BOTTLE (10144-594-15)
ZANAFLEX tizanidine hydrochloride TABLET;ORAL 020397 NDA PD-Rx Pharmaceuticals, Inc. 55289-612 55289-612-10 10 TABLET in 1 BOTTLE, PLASTIC (55289-612-10)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 4MG BASE
Approval Date:Nov 27, 1996TE:ABRLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:DISCNDosage:TABLET;ORALStrengthEQ 2MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**
Approval Date:Feb 4, 2000TE:RLD:Yes

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
Covington
McKesson
Queensland Health
Medtronic
US Department of Justice
Johnson and Johnson
Federal Trade Commission
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot